AVIADOBIO LTD

1. AVIADOBIO LTD 2021-12-02 → present
2. NEUROGENEUS LTD 2019-12-20 → 2021-12-02

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In preparing the financial statements, the directors have assessed the ability of the company and its subsidiary undertakings (collectively "the group") to continue as a going concern for a period of at least 12 months from the date of approval of these financial statements. This assessment included detailed review of cash flow forecasts and funding arrangements. The group is currently in a research and development phase, which has resulted in an operating loss for the period. Consistent with the group's lifecycle stage, it continues to operate with net cash outflows, however, licensing income is now being recognised.”

Group structure

1. AVIADOBIO LTD · parent
   1. Neurogeneus Ltd 100% · London, England · Research and experimental development on biotechnology
   2. AviadoBio Inc. 100% · Austin, Texas, USA · Research and experimental development on biotechnology

Significant events

• “During the year the company had continued to advance its portfolio of gene therapies for neurodegenerative diseases. This had included the continued dosing of patients in ASPIRE-FTD a Phase 1/2 human clinical trial that had evaluated AVB-101 in Frontotemporal dementia patients, and the presentation of early clinical experience data at a scientific forum in late 2024.”
• “The company successfully raised $61,200,000 in funding through two key transactions.”
• “In April 2025, as part of the strategic partnership with Astellas Pharma Inc., the Second Option Upfront Payment of $10,000,000 was received.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

13

last 12 months

Capital events

9

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  +67.4%

  £28,188,800 → £47,190,003

• Net assets

  +18.6%

  £30,586,307 → £36,277,183

• Employees

  +1.6%

  64 → 65

• Operating profit

  +1.9%

  -£22,725,259 → -£22,302,835

• Profit before tax

  +2.8%

  -£22,315,481 → -£21,684,439

• Wages

  +5.3%

  £8,289,148 → £8,724,844

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers